SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001636282-24-000021
Filing Date
2024-04-01
Accepted
2024-04-01 16:06:29
Documents
19
Period of Report
2024-05-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A syre-20240401.htm   iXBRL DEF 14A 572031
6 syre-20240401_g1.jpg GRAPHIC 24936
7 syre-20240401_g2.jpg GRAPHIC 57992
8 syre-20240401_g3.jpg GRAPHIC 59111
9 syre-20240401_g4.jpg GRAPHIC 394534
10 syre-20240401_g5.jpg GRAPHIC 109093
  Complete submission text file 0001636282-24-000021.txt   2744942

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT syre-20240401.xsd EX-101.SCH 4523
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT syre-20240401_def.xml EX-101.DEF 7227
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT syre-20240401_lab.xml EX-101.LAB 9103
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT syre-20240401_pre.xml EX-101.PRE 5824
22 EXTRACTED XBRL INSTANCE DOCUMENT syre-20240401_htm.xml XML 90702
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37722 | Film No.: 24809164
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)